INTRODUCTION

On December 31, 2019, a novel coronavirus disease caused by severe acute respiratory syndrome type 2 coronavirus (SARS-CoV-2) was first reported in China. On January 30, 2020, the World Health Organization (WHO) announced that the new coronavirus pneumonia epidemic was listed as a "public health emergency of international concern," and on February 11, the WHO officially named the disease as Coronavirus disease 2019 (COVID-19). COVID-19 had a devastating impact on almost all countries in the world. Because the new coronavirus is highly contagious and spreads quickly, it is not easy to find in mild cases and asymptomatic infections. Also, it is easy to cause "hidden" transmission in communities and medical institutions. The virus may gradually evolve into a seasonal low-level epidemic. Even if the virus can be completely eliminated from the population, the transmission mechanism from the host to the person is still unclear due to the population's general susceptibility. There is a risk of recurrence or periodic epidemics. Vaccines need to be administered as soon as possible. Globally, 7.8 billion people are at risk of SARS-CoV-2 infection and the morbidity and death of COVID-19. People are looking forward to developing an effective and safe COVID-19 vaccine to contain this COVID-19 pandemic and prevent another outbreak of the epidemic. More than 200 COVID-19 vaccines have been listed in the WHO as under development. The expectations for effective prophylactic COVID-19 vaccines are very high. Vaccines proven effective and safe in phase III clinical trials may enter the market in 2021. Several vaccines have been approved for marketing, such as Pfizer-BioNTech's BNT162b2 and Moderna's mRNA-1273.
The design of the COVID-19 vaccines must take into account both humoral and cellular immunity. In addition, COVID-19 is mainly spread through the respiratory tract and contact, so the role of mucosal immunity in preventing viral infections should be paid more attention. The virus contains four structural proteins. They are Spike S protein, Envelope E protein, Membrane/matrix protein, and Nucleocapsid N protein. The S protein has two subsections, S1 and S2. The S protein binds to specific receptors, causing the virus to infect cells. The neutralizing antibody against the S protein can block this process and prevent the virus from invading. S protein can also effectively stimulate T-cell immune response, so it is the most important target antigen for vaccine design. N and M proteins have also been shown to induce the body to produce an efficient cellular immune response.

SARS-CoV-2 is unusual for a respiratory virus that binds to a receptor, angiotensin-converting enzyme 2 (ACE2). ACE2 can be expressed in virtually all organs, but especially in the lungs, gut, and brain. Therefore, unlike most respiratory viruses, SARS-CoV-2 has a wider biological distribution and may cause considerable damage outside the respiratory system. It adversely affects the genitourinary system, digestive system, circulatory system, and central nervous system. The universality of the distribution of ACE2 receptors leads to multiple changes in symptoms, such as dyspnea, headache, diarrhea, venous thromboembolism, and high blood pressure. The S protein binds to ACE2 on cells to mediate infection. The S1 subunit contains the receptor-binding domain (RBD) and is responsible for initial attachment to the host cells through the ACE2 receptor, while the S2 subunit promotes viral fusion with cells to initiate infection. The S protein is a frequent vaccine target as it is expected that antibodies binding to the correct epitope on the S protein may be neutralizing and block intercellular viral spread.

3 | TYPES OF VACCINES

The vaccines currently under study can be roughly divided into the following categories. Different types of vaccines have their characteristics (Table 1).

3.1 | DNA vaccines

DNA vaccines can enter cells like viral infections and use the host protein translation system to generate target antigens. As an endogenous immunogen, it can induce humoral and cellular immune responses at the same time. Given the advantages of nucleic acid vaccines, DNA vaccines do not require live viruses, so safety is improved. DNA vaccines insert genes encoding foreign antigens into plasmids containing eukaryotic expression elements and then directly introduce the plasmids into humans or animals, allowing them to express antigen proteins in host cells and induce immune responses to prevent diseases.

The manufacturing process of plasmid DNA is relatively straightforward, and the double-strand DNA molecules are more stable than the virus and can be freeze-dried for long-term storage. DNA vaccine vaccination method limits its application. Since the vaccine is mainly distributed in the intercellular space after vaccination, only a very small amount can enter the cell to produce protein immunogen, so the immune effect is greatly reduced. The plasmid DNA vaccine’s main prohibitory factor is the low transfection efficacy, which requires transfection modalities. For example, Inovio's COVID-19 vaccine candidate, INO-4800, uses a handheld electroporation device, CELLECTRA. The vaccine will be injected intradermally along with the electrodes. An electric pulse is then applied to open the cell membrane so that the plasmid can enter the cells. Using an established device may allow fast launch in clinical trials, but it also brings other obstacles to large-scale vaccination. Although nucleic acid vaccines can effectively induce systemic immune responses, their immunogenicity is weak, and mucosal immune responses are not easy to produce. Although a few animal DNA vaccines have been on the market, no human DNA vaccine has been approved for marketing so far. Combination with other vaccines will achieve better immune effects.

3.2 | mRNA vaccines

Compared with DNA vaccines that need to enter the nucleus, mRNA vaccines only need to enter the cytoplasm to achieve target antigens’ expression, so they are theoretically safer. In recent years, mRNA vaccines have been developed rapidly. Although the mRNA vaccines for rabies virus and influenza virus have completed phase I clinical evaluation, the immune effect is not satisfactory, such as a relatively high proportion of headaches, fatigue, and side effects such as muscle pain. The immune protection generated by the vaccine declined rapidly within one year, and no cellular immune response was detected. Therefore, it is necessary to improve further the immune efficacy and long-term protection of mRNA vaccines. So far, there is no mRNA vaccine on the market. However, the research of mRNA vaccines has been in the process of exploration and advancement. Many institutions at home and abroad have quickly initiated the research and development of COVID-19 mRNA vaccines. The mRNA vaccine developed by the National Institute of Allergy and Infectious Diseases (NIAID) and Moderna has taken the lead to initiate a phase I clinical trial. Moderna's vaccine, mRNA-1273, specifically encodes the S antigen's prefusion form, including a transmembrane anchor and an entire S1–S2 cleavage site.

3.3 | Non-replicating viral vector vaccines

One of the most explored viral vector options is the Adenovirus (Ad), currently being used by both CanSino and Oxford/ AstraZeneca.
| Types of vaccines | Mechanisms | Advantages                                                                 | Disadvantages                                                                 | Examples                  |
|------------------|------------|-----------------------------------------------------------------------------|------------------------------------------------------------------------------|---------------------------|
| DNA vaccines     | DNA vaccines can enter cells like viral infections and use the host protein translation system to generate target antigens. It can induce humoral and cellular immune responses at the same time. | DNA vaccines do not require live viruses. The manufacturing process of plasmid DNA is relatively straightforward, and the double-strand DNA molecules are more stable than the virus and can be freeze-dried for long-term storage. | DNA vaccine vaccination method limits its application | INO–4800                  |
| mRNA vaccines    | mRNA vaccines need to enter the cytoplasm to achieve target antigens' expression | theoretically safer                                                                 | The immune effect is not satisfactory, and a relatively high proportion of side effects. | mRNA–1273                |
| Non-replicating viral vector vaccines | It can encode for the full-length S protein of SARS-CoV-2. | The effectiveness of this vaccine is relatively high. | It may not effective for people with recessive infectious viruses. | Ad5-nCoV                  |
| Inactivated vaccines | Inactivated vaccines are mainly obtained through three inactivation methods, which make it lose its infectivity and toxicity while maintaining immunogenicity. | They are easy to prepare and can efficiently cause humoral immune responses. | Vaccine production requires the operation of high concentrations of live viruses, which poses a certain biological safety risk. The T-cell immune response caused by inactivated vaccines is generally weak. | The inactivated SARS-CoV-2 vaccine (Vero cells) |
| Live attenuated vaccines | Live attenuated vaccine reduces virus virulence through point mutation or deletion of crucial virus protein but does not affect its immunogenicity and replication ability. | This vaccine program has very good immunogenicity and can induce systemic immunity and mucosal immune response, and the immunity is lasting. | It is possible to restore virulence in the body due to retrograde mutations | Polio vaccine              |
| Subunit vaccines | The antigen protein of the pathogen is expressed and purified through genetic engineering to induce an immune response. | Subunit vaccines are composed of purified recombinant proteins and are considered to be the safest vaccines. It has good safety and immunogenicity. | As a non-endogenous antigen, subunit vaccines cannot be presented through MHC-I and cannot effectively produce sensitized cytotoxic T cells (CTL). | Recombinant subunit SARS-CoV–2 vaccine (CHO cells) |
| Trained immunity-based vaccines | Trained immunity-based vaccines can activate the adaptive immune system and provide pathogen-specific protection | / | The production standards of the BCG vaccine will be different. | BCG vaccine               |
Adenovirus is common cold viruses with a double-stranded DNA genome. CanSino is using Ad type 5 (Ad5) and named the vaccine Ad5-nCoV.\textsuperscript{22} Ad5-nCoV can encode for the full-length S protein of SARS-CoV-2. This gene is derived from the Wuhan-Hu-1 sequence of SARS-CoV-2 and is cloned into the E1- and E3-deleted Ad5 vector together with the tissue plasminogen activator signal peptide.\textsuperscript{16} The effectiveness of this vaccine is relatively high, but the disadvantage is that it may not be effective for people with recessive infectious viruses.

### 3.4 Inactivated vaccines

Inactivated vaccines are the most classic form of vaccines. They are easy to prepare and can efficiently cause humoral immune responses. They are often the first choice for new infectious diseases. Inactivated vaccines are mainly obtained through three inactivation methods, such as formaldehyde, β-propiolactone, and ultraviolet. SARS and MERS inactivated vaccines can cause mice, hamsters, ferrets, and monkeys to produce high-titer neutralizing antibodies. The SARS-inactivated vaccine has completed phase I clinical trials, proving that it is safe in humans and can induce neutralizing antibodies' production.\textsuperscript{23} However, the T-cell immune response caused by inactivated vaccines is generally weak. Previous studies have shown that SARS- and MERS-inactivated vaccines cannot effectively stimulate the body to produce cellular immune responses.\textsuperscript{24,25} Although high titers of serum neutralizing antibodies are produced, the protective effect is also not satisfied.\textsuperscript{25} Some studies have found that the MERS-inactivated vaccine can cause pathological allergic reactions in mice's lungs.\textsuperscript{26} Currently, the inactivated SARS-CoV-2 vaccine (Vero cells) is being used. In addition, vaccine production requires the operation of high concentrations of live viruses, which poses a certain biological safety risk.

### 3.5 Live attenuated vaccines

Live attenuated vaccine reduces virus virulence through point mutation or deletion of crucial virus protein but does not affect its immunogenicity and replication ability. This vaccine program has very good immunogenicity and can induce systemic immunity and mucosal immune response, and the immunity is lasting. Several live attenuated vaccines have been on the market, including yellow fever, smallpox, measles, polio, mumps, rubella, and chickenpox. The SARS live attenuated vaccine will recover its virulence after continuous passage in cells or mice, suggesting that the vaccine scheme has a greater biological safety risk.\textsuperscript{27} Without sufficient evidence to ensure that live attenuated vaccines will not regain strength, this strategy is not currently recommended for COVID-19 vaccine development.

### 3.6 Subunit vaccines

Subunit vaccines are composed of purified recombinant proteins and are considered to be the safest vaccines. There are currently several subunit vaccines on the market, including hepatitis B, hepatitis E, and human papillomavirus vaccines. SARS and MERS subunit vaccines can produce high-titer neutralizing antibodies in mice, and nasal or oral vaccination can also induce a mucosal immune response, thereby more effectively blocking the virus transmission through the respiratory tract. The data also prove the protective efficacy of mucosal vaccination better than intramuscular inoculation.\textsuperscript{28-31} However, as a non-endogenous antigen, subunit vaccines cannot be presented through MHC-I and cannot effectively produce sensitized cytotoxic T cells (CTL). Considering the key role of cellular immunity in clearing coronavirus infections, the subunit vaccine of COVID-19 is best used in conjunction with other platform vaccines. It is recommended to include nasal and oral mucosal vaccination routes to activate mucosal immune responses.

### 3.7 Trained immunity-based vaccines

Trained immunity-based vaccines can activate the adaptive immune system and provide pathogen-specific protection.\textsuperscript{32,33} Currently, Bacille Calmette-Guerin (BCG), a vaccine against tuberculosis, can induce trained immunity against COVID-19 and is currently undergoing clinical evaluation, which will take time to prove.\textsuperscript{34} Even if the BCG vaccine is effective against COVID-19, it also faces unique challenges. That is, the production standards of the BCG vaccine will vary from country to country, and it is not clear whether certain quality standards are required to provide protection against COVID-19.\textsuperscript{35}

### 4 QUESTIONS AND THOUGHTS

There are always various problems in the development of vaccines. Among them, the later application and evaluation of vaccines are particularly prominent.

### 4.1 Dosage problems

Many phase III studies failed because of incorrect identification of the dose that best balances safety and efficacy.\textsuperscript{36} For example, the dosing regimen for the mRNA vaccine is still under study. The 250μg dose does not seem to have significantly higher antibody titers than the 100μg dose, but it is related to a higher proportion of serious systemic adverse events. As the researchers pointed out, carefully evaluate doses of 100 μg or lower to define the regimen that provides the most appropriate benefit-risk profile for the vaccine. In this case, another special dosage consideration is age. The immune function that declines with age may lead to a greater risk of severe COVID-19 in the elderly and lead to low vaccine responses. As observed in the influenza vaccine, a large dose of the COVID-19 vaccine needed to protect the elderly\textsuperscript{27} effectively? It may take some time to solve these problems.
4.2 | Adverse reactions of vaccines

The vaccine also has adverse reactions such as redness, swelling, muscle pain, and fever. The strategic objectives of the COVID-19 vaccine roadmap formulated by WHO include a series of preferred and most basic requirements such as vaccine safety and effectiveness. The preferred requirements for safety/reactogenicity include "safety and reactogenicity sufficient to provide a highly favorable benefit/risk profile in the context of the observed vaccine efficacy and only mild, transient related to adverse vaccination events without serious adverse events". The most basic requirements for safety/reactogenicity include the benefits of vaccines outweigh the potential safety hazards. The long-term results were a safety that is sufficient to provide highly favorable benefits/risk characteristics in the context of the observed vaccine efficacy and immunogenicity. 

There were no serious adverse events related to vaccination. The preferred requirements for effectiveness include the protection effectiveness in the population is at least 70%, and the same is true for the elderly. If it is an outbreak treatment, the protective effect must appear within two weeks and last for at least one year. The most basic requirements include the population's protective effect is at least about 50% for at least six months.

4.3 | Clinical trials and Efficacy evaluation (endpoint observation)

Key considerations for the safety of COVID-19 vaccine research and development were important. Most of the preventive vaccines' targets are healthy individuals, and their safety is the most important issue in vaccine development and clinical trials. The State Drug Administration has issued the "Notice on the Guidelines for the Classification of Adverse Events in Clinical Trials of Preventive Vaccines" and other relevant regulations to guide vaccine development and clinical trials. In the past, the development of inactivated measles vaccines and respiratory syncytial virus vaccines, there has been an increase in antibody-dependent infection. Therefore, when studying COVID-19 vaccines, attention should be paid to whether they will cause similar immunopathological reactions. Long-term safety observations are required.

Although the Food and Drug Administration (FDA) of the United States recommends defining the COVID-19 endpoint as virologically confirmed SARS-CoV-2 infection accompanied by one or more of 11 Symptoms, trialists have the latitude in selecting specific symptoms and severities to trigger virologic testing. It is important to define a common COVID-19 endpoint that can be used consistently across trials, not only to interpret results but also to facilitate trials' meta-analyses.

4.4 | Vaccine application

Preventive vaccines will control COVID-19 is justified by the impact of vaccines on preventing disability and death from infectious diseases. Even if vaccine supply is no longer an obstacle, people's hesitation to vaccinate remains a major challenge.

In first-line medical staff at the University of Texas Southwestern Medical Center, 234 of the 8,969 unvaccinated employees were infected (2.61%), and only 4 of the 8,121 vaccinated employees were infected (0.05%), and one research was in California also got similar results.

In a hospital in Jerusalem, among the medical staff who received two doses of the vaccine, the number of new COVID-19 cases had decreased significantly despite the sudden increase of the B.1.1.7 variant (see up to 80% of cases). These data show that vaccination had largely protected frontline medical workers in high-risk environments. Therefore, vaccination is particularly important in global epidemic prevention work.

4.5 | Travel immunization

If the epidemic situation is well controlled, and the future epidemic situation is mainly imported, entry and exit personnel should be the target of implementing the immunization strategy, and close contacts of entry personnel should be used as vaccinations.

4.6 | Immunization after exposure

If it is confirmed that the COVID-19 vaccine has the effect of preventing or alleviating the symptoms of the disease on the exposed subjects, it is possible to consider adopting a post-exposure immunization strategy for close contacts of confirmed COVID-19 cases. Therefore, it is necessary to evaluate the protective effect of COVID-19 vaccines, especially vaccines developed by new technologies, to determine post-exposure vaccination's scientific nature.

4.7 | Pre-exposure immunization

For subjects who may be exposed to COVID-19 patients or high-risk infections, such as medical staff in fever clinics, COVID-19
4.8 | Emergency immunization

In the event of a COVID-19 epidemic, under the premise of confirming the emergency immunization effect of the COVID-19 vaccine, an emergency immunization strategy can be considered for the population in the epidemic area. Therefore, in the early stage of vaccine marketing, it is necessary to carry out the effect evaluation of emergency immunization, especially the effect evaluation of the ring immunization strategy's implementation.

In addition to the above four immunization strategies for pandemic immunization, because COVID-19 is susceptible to the entire population, this feature is different from the H1N1 pandemic. In the case of vaccine supply in batches, comprehensive consideration of protection priorities, reducing deaths and cluster outbreaks determine the targets and immunization procedures for mass pandemic vaccination.

5 | CONCLUSION

In short, the successful development of the COVID-19 vaccine concerns almost all countries and people in the world. We must do an excellent job of researching the immunogenicity and immune reactivity of the vaccines.

ACKNOWLEDGEMENTS

Not applicable.

CONFLICTS OF INTEREST

The authors declare no conflicts of interest.

AUTHORS CONTRIBUTIONS

XCH designed the current study and was major contributors in writing the manuscript. PFX and QY were responsible for the modification and giving final approval of the manuscript. All authors read and approved the final manuscript.

DATA AVAILABILITY STATEMENT

Data sharing is not applicable to this article as no new data were created or analyzed in this study.

ORCID

Xiucui Han https://orcid.org/0000-0002-1630-4047

REFERENCES

1. Shereen MA, Khan S, Kazmi A, et al. COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. J Adv Res. 2020;24:91-98.

2. WHO. Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV) [EB/OL]. (2020-01-23) [2020-02-25]. https://www.who.int/news-room/detail/23-01-2020-statement-on-the-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov)

3. Draft landscape of COVID-19 candidate vaccines; https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.

4. Clinical Trials. Draft landscape of COVID-19 candidate vaccines [EB/OL]. (2020 - 09 - 29). https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.

5. Li F, Li W, Farzan M, et al. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science. 2005;309(5742):1864-1868.

6. Agnihotram S, Gopal R, Yount BL Jr, et al. Evaluation of serologic and antigenic relationships between middle eastern respiratory syndrome coronavirus and other coronaviruses to develop vaccine platforms for the rapid response to emerging coronaviruses. J Infect Dis. 2014;209(7):995-1006.

7. Li W, Moore MJ, Vasiliou N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426(6965):450-454.

8. Du L, Yang Y, Zhou Y, et al. MERS-CoV spike protein: a key target for antivirals. Expert Opin Ther Targets. 2017;21(2):131-143.

9. Wang Z, Yuan Z, Matsumoto M, et al. Immune responses with DNA vaccines encoded different gene fragments of severe acute respiratory syndrome coronavirus in BALB/c mice. Biochem Biophys Res Commun. 2005;327(1):130-135.

10. Zhu MS, Pan Y, Chen HQ, et al. Induction of SARS-nucleoprotein-specific immune response by use of DNA vaccine. Immunol Lett. 2004;92(3):237-243.

11. Kim TW, Lee JH, Hung CF, et al. Generation andcharacterization of DNA vaccines targeting the nucloacapsid protein of severe acute respiratory syndrome coronavirus. J Virol. 2004;78(9):4638-4645.

12. Kuba K, Imai Y, Penninger JM. Angiotensin-converting enzyme 2 in lung diseases. Curr Opin Pharmacol. 2006;6(3):271-276.

13. Wang J, Zhao S, Liu M, et al. ACE2 expression by colonic epithelial cells is associated with viral infection. Immunity Energy Metab. 2020, 2020.02.05.20020545.

14. Xia H, Lazartigues E. Angiotensin-converting enzyme 2 in the brain: properties and future directions. J Neurochem. 2008;107(6):148214-148294.

15. Zhang Y, Geng X, Tan Y, et al. New understanding of the damage of SARS-CoV-2 infection outside the respiratory system. Biomed Pharmacother. 2020;127: 110195.

16. Astuti I, Ysrail. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): an overview of viral structure and host response. Diabetes Metab Syndr. 2020;14(4):407-412.

17. Suschak JJ, Williams JA, Schmaljohn CS. Advancements in DNA vaccine vectors, non-mechanical delivery methods, and molecular adjuvants to increase immunogenicity. Hum Vaccin Immunother. 2017;13(12):2837-2848.

18. INOVIO Expands manufacturing of COVID-19 DNA vaccine INO-4800 With New Funding from CEPI [Internet]. [cited 2020 May 18]. Available from: http://ir.inovio.com/news-releases/news-releases-details/2020/INOVIO-Expands-Manufacturing-of-COVID-19-DNA-Vaccine-INO-4800-With-New-Fundingfrom-CEPI/default.aspx

19. Alberer M, Gnad-Vogt U, Hong HS, et al. Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial. Lancet. 2017;390(10101):1511-1520.

20. Feldman RA, Fuhr R, Smolenev I, et al. mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are
immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials. Vaccine. 2019;37(25):3326-3334.

21. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. N Engl J Med. 2020;383(20):1920-1931.

22. Zhu FC, Li YH, Guan XH, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020;395(10240):1845-1854.

23. Deng Y, Lan J, Bao L, et al. Enhanced protection in mice induced by immunization with inactivated whole viruses compare to spike protein of middle east respiratory syndrome coronavirus. Emerg Microbes Infect. 2018;7(1):60.

24. Xiong S, Wang YF, Liu XJ, et al. Early immunoresponse of BALB/C mice to inactivated SARS vaccines prepared with different adjuvants. Chin J Immun. 2004;20(6):413-417.

25. See RH, Petric M, Lawrence DJ, et al. Severe acute respiratory syndrome vaccine efficacy in ferrets: whole killed virus and adenovirus vectored vaccines. J Gen Virol. 2008;89(Pt 9):2136-2146.

26. Agrawal AS, Tao X, Algaissi A, et al. Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus. Hum Vaccin Immunother. 2016;12(9):2351-2356.

27. Jimenez-Guareño JM, Regla-Nava JA, Nieto-Torres JL, et al. Identification of the mechanisms causing reversion to virulence in an attenuated SARS-CoV for the design of a genetically stable vaccine. PLoS Pathog. 2015;11(10):e1005215.

28. Ma C, Li Y, Wang L, et al. Intranasal vaccination with recombinant vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020;395(10240):1845-1854.

29. Li E, Chi H, Huang P, et al. A novel bacterium-like particle vaccine displaying the MERS-CoV receptor-binding domain induces specific mucosal and systemic immune responses in mice. Viruses. 2019;11(9):799.

30. New RRC, Moore BD, Butcher W, et al. Antibody-mediated protection against MERS-CoV in the murine model. Vaccine. 2019;37(30):4094-4102.

31. Wang Y, Tai W, Yang J, et al. Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection. Hum Vaccin Immunother. 2017;13(7):1615-1624.

32. Sánchez-Ramón S, Conejero L, Netea MG, et al. Trained immunity-based vaccines: a new paradigm for the development of broad-spectrum anti-infectious formulations. Front Immunol. 2018;9:2936.

33. Quintin J, Saeed S, Martens JHA, et al. Candida albicans infection affords protection against reinfection via functional reprogramming of monocytes. Cell Host Microbe. 2012;12(2):223-232.

34. Texas AandM University. BCG vaccine for health care workers as defense against COVID 19 (BADAS). [Internet]. 2020 [cited 2020 May 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT04348370

35. Angelidou A, Conti MG, Diray-Arce J, et al. Licensed Bacille Calmette-Guérin (BCG) formulations differ markedly in bacterial viability, RNA content and innate immune activation. Vaccine. 2020;38(9):2229-2240.

36. Musuamba FT, Manolis E, Holford N, et al. Advanced methods for dose and regimen finding during drug development: summary of the EMA/EFPIA workshop on dose finding (London 4–5 December 2014). CPT Pharmacometrics Syst Pharmacol. 2017;6(7):418-429.

37. DiazGranados CA, Dunning AJ, Kimmel M, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med. 2014;371(7):635-645.

38. Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396(10249):467-478.

39. Al-Kassmy J, Pedersen J, Kobinger G. Vaccine Candidates against Coronavirus Infections. Where Does COVID-19 Stand? Viruses. 2020;12(8):861.

40. World Health Organization. WHO target product profiles for COVID-19 vaccines (version 3) [EB/OL]. [2020-04-29] [2020-07-16]. https://www.who.int/publications/m/item/who-target-produ ct-profiles-for-covid-19-vaccines

41. National Medical Products Administration. Announcement on Issuing the Guidelines for the Classification Standards for Adverse Events in Clinical Trials of Preventive Vaccines (No. 102, 2019) [S]. 2019.

42. Zhao K. Research on SARS vaccine and its related immune problems. Chinese J Microbiol Immunol. 2003;23(6):407-408.

43. U.S. Department of Health and Human Services, U.S. Food and Drug Administration, Center for Biologics Evaluation and Research. Development and Licensure of Vaccines to Prevent COVID-19: Guidance for Industry. Accessed at www.fda.gov/media/139638/download on July 24 2020.

44. Huqing W. Review of immunization strategies and considerations for future immunization strategies with COVID-19 vaccines. Chinese J Vaccines Immunization. 2020;26(5):583-589.

45. Chan M. Ten Years in Public Health 2007–2017 (World Health Organization). 2017.

46. Daniel W, Nivet M, Warner J, et al. Early evidence of the effect of SARS-CoV-2 vaccine at one medical center. N Engl J Med. 2021;384(20):1962-1963.

47. Keehner J, Horton LE, Pfeffer MA, et al. SARS-CoV-2 infection after vaccination in health care workers in California. N Engl J Med. 2021;384(18):1774-1775.

48. Benenson S, Oster Y, Cohen MJ, et al. BNT162b2 mRNA Covid-19 vaccine against SARS-CoV-2 - Preliminary Report. Vaccine. 2019;37(30):4094-4102.

49. How to cite this article: HAN ET AL. Analysis of COVID-19 vaccines: Types, thoughts, and application. J Clin Lab Anal. 2021;35:e23937. https://doi.org/10.1002/jcla.23937